PDF(Pubmed)
Abstract：
Polypharmacy of additional psychotropics alongside the main treatment drug (antipsychotics in schizophrenia and antidepressants in major depressive disorder) is common in Japan. Our goal is to align psychotropic prescription in Japan with international standards, while reducing the differences between facilities. To achieve this goal, we aimed to compare prescriptions at the time of hospital admission and discharge.
Data on prescriptions at admission and discharge from 2016 to 2020 were collected. We divided the patients into four groups: (1) mono_mono group, monotherapy of the main drug at admission and discharge; (2) mono_poly group, monotherapy at admission and polypharmacy at discharge; (3) poly_poly group, polypharmacy at admission and discharge; and (4) poly_mono group, polypharmacy at admission and monotherapy at discharge. We compared the changes in dosage and number of psychotropics among the four groups.
For both schizophrenia and major depressive disorder, the patients who received monotherapy with the main drug at admission were likely to receive main drug monotherapy at discharge and vice versa. For schizophrenia, the polypharmacy was prescribed more often in the mono_poly group than that in the mono_mono group. The prescription was not changed at all for more than 10% of the patients.
It is critical to avoid a polypharmacy regimen to ensure that guideline-compliant treatment is provided. We expect higher rates of monotherapy with the main drug after the EGUIDE lectures.
The study protocol was registered in the University Hospital Medical Information Network Registry (UMIN000022645).
Data on prescriptions at admission and discharge from 2016 to 2020 were collected. We divided the patients into four groups: (1) mono_mono group, monotherapy of the main drug at admission and discharge; (2) mono_poly group, monotherapy at admission and polypharmacy at discharge; (3) poly_poly group, polypharmacy at admission and discharge; and (4) poly_mono group, polypharmacy at admission and monotherapy at discharge. We compared the changes in dosage and number of psychotropics among the four groups.
For both schizophrenia and major depressive disorder, the patients who received monotherapy with the main drug at admission were likely to receive main drug monotherapy at discharge and vice versa. For schizophrenia, the polypharmacy was prescribed more often in the mono_poly group than that in the mono_mono group. The prescription was not changed at all for more than 10% of the patients.
It is critical to avoid a polypharmacy regimen to ensure that guideline-compliant treatment is provided. We expect higher rates of monotherapy with the main drug after the EGUIDE lectures.
The study protocol was registered in the University Hospital Medical Information Network Registry (UMIN000022645).
摘要：
背景：在日本，除了主要治疗药物（精神分裂症中的抗精神病药和重度抑郁症中的抗抑郁药）之外，其他精神药物的多药疗法很常见。我们的目标是使日本的精神药物处方与国际标准保持一致，同时减少设施之间的差异。为了实现这一目标,我们旨在比较入院和出院时的处方。
方法：收集2016年至2020年入院和出院时的处方数据。我们将患者分为四组：(1)mono_mono组，入院和出院时主要药物的单药治疗；(2)单聚基团，入院时单药治疗和出院时多重用药；(3)多聚组，入院和出院时的多重用药；和(4)多重组，入院时的多重用药和出院时的单药治疗。我们比较了四组中精神药物的剂量和数量的变化。
结果：对于精神分裂症和重度抑郁症，入院时接受主药单药治疗的患者很可能在出院时接受主药单药治疗,反之亦然.对于精神分裂症，与单单组相比，单多组开多药方的处方频率更高。超过10％的患者根本没有改变处方。
结论：避免多重用药方案以确保提供符合指南的治疗是至关重要的。我们预计在EGUIDE讲座后使用主要药物进行单药治疗的比率更高。
背景：研究方案已在大学医院医学信息网络注册（UMIN000022645）中注册。
方法：收集2016年至2020年入院和出院时的处方数据。我们将患者分为四组：(1)mono_mono组，入院和出院时主要药物的单药治疗；(2)单聚基团，入院时单药治疗和出院时多重用药；(3)多聚组，入院和出院时的多重用药；和(4)多重组，入院时的多重用药和出院时的单药治疗。我们比较了四组中精神药物的剂量和数量的变化。
结果：对于精神分裂症和重度抑郁症，入院时接受主药单药治疗的患者很可能在出院时接受主药单药治疗,反之亦然.对于精神分裂症，与单单组相比，单多组开多药方的处方频率更高。超过10％的患者根本没有改变处方。
结论：避免多重用药方案以确保提供符合指南的治疗是至关重要的。我们预计在EGUIDE讲座后使用主要药物进行单药治疗的比率更高。
背景：研究方案已在大学医院医学信息网络注册（UMIN000022645）中注册。
